References of "Coucke, Philippe"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailTumor volume and/orTumor thickness should be considered in TNM classification of rectal tumors
COUCKE, Philippe ULg; Zouhair, A; Bouzourene, H et al

Poster (2002)

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailRadiation-associated synovial-sarcoma: clinicopathological and molecular analysis of two cases.
Egger, J-F; Coindre, J-M; Benhattar, J et al

in Modern Pathology : An Official Journal of the United States & Canadian Academy of Pathology, Inc (2002), 15(9), 998-1004

Development of a soft-tissue sarcoma is an infrequent but well-known long-term complication of radiotherapy. Malignant fibrous histiocytomas, extraskeletal osteosarcomas, fibrosarcomas, malignant ... [more ▼]

Development of a soft-tissue sarcoma is an infrequent but well-known long-term complication of radiotherapy. Malignant fibrous histiocytomas, extraskeletal osteosarcomas, fibrosarcomas, malignant peripheral nerve sheath tumors, and angiosarcomas are most frequently encountered. Radiationassociated synovial sarcomas are exceptional. We report the clinicopathologic, immunohistochemical, and molecular features of two radiationassociated synovial sarcomas. One tumor developed in a 42-year-old female 17 years after external irradiation was given for breast carcinoma; the other occurred in a 34-year-old female who was irradiated at the age of 7 years for a nonneoplastic condition of the left hand. Both lesions showed morphologic features of monophasic spindle cell synovial sarcoma, were immunoreactive for cytokeratins, epithelial membrane antigen, CD99, CD117 (c-kit), and bcl-2 and bore the t(X;18) (SYT-SSX1) translocation. We conclude that synovial sarcoma has to be added to the list of radiation-associated soft-tissue sarcomas. Mod Pathol 2002;15(9):998–1004 [less ▲]

Detailed reference viewed: 12 (1 ULg)
Full Text
Peer Reviewed
See detailRole of methalothionein in irradiated human rectal carcinoma.
Bouzourene, H; Chabert, P; Gebhardt, S et al

in Cancer (2002), 95(5), 1003-1008

BACKGROUND. Metallothioneins (MT) are low-molecular weight, metal-binding proteins that play a role in cellular proliferation and differentiation, as well as in cellular defense mechanisms. They act as ... [more ▼]

BACKGROUND. Metallothioneins (MT) are low-molecular weight, metal-binding proteins that play a role in cellular proliferation and differentiation, as well as in cellular defense mechanisms. They act as scavengers of free radicals produced by irradiation. A number of in vitro and in vivo studies have linked overexpression of cellular MT with tumor cell resistance to radiation. This is the first study that investigates whether MT expression is involved in the radioresistance of rectal carcinoma. METHODS. Using a mouse monoclonal antibody, MT expression was analyzed by immunohistochemistry on surgical samples (n 85) from 85 patients with locally advanced rectal carcinoma who were treated preoperatively with a hyperfractionated and accelerated radiotherapy schedule and on tumor biopsies (n 13) obtained before treatment. The potential correlations between MT expression and pathologic variables and survival were examined. RESULTS. MT were expressed strongly in both the cytoplasm and nucleus of tumor cells in 7 biopsy and 42 surgical samples. A comparison of MT expression in biopsy and surgical specimens showed that MT expression did not change after irradiation in most cases. Against all expectations, MT were expressed more frequently in tumors from responders than in those from the nonresponders (P 0.02). There was no correlation between MT expression and tumor stage, histology after radiotherapy, or survival. CONCLUSION. These findings do not support the hypothesis that MT overexpression at the end of radiotherapy is a marker for radiation resistance. Cancer 2002;95: 1003–8. © 2002 American Cancer Society. DOI 10.1002/cncr.10780 [less ▲]

Detailed reference viewed: 28 (0 ULg)
Full Text
Peer Reviewed
See detailRepeated intracoronary beta radiation for recurrent in-stent restenosis.
De Benedetti, E; Latchem, D; Roguelov, C et al

in Catheterization and Cardiovascular Interventions (2002), 55(2), 233-236

More than 70% of percutaneous coronary interventions are followed by a stent implantation. In-stent restenosis still occurs in 20-30% of patients and remains a therapeutic challenge. At present only ... [more ▼]

More than 70% of percutaneous coronary interventions are followed by a stent implantation. In-stent restenosis still occurs in 20-30% of patients and remains a therapeutic challenge. At present only vascular brachytherapy has been shown to be an effective treatment option. We report here one case of recurrent in-stent restenosis after vascular brachytherapy that was successfully treated by a second beta radiation treatment. Cathet Cardiovasc Intervent 2002;55:233–236. © 2002 Wiley-Liss, Inc. [less ▲]

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailRadiothérapie vasculaire : un nouveau standard
Coucke, Philippe ULg; Hu Phuoc, Do; Urban, Ph. et al

in Médecine et Hygiène (2001), (3000),

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailFractionated irradiation combined with carbogen breathing and nicotinamide of two human glioblastomas grafted in nude mice
SUN, Lin-Quan; BUCHEGGER, Franz; COUCKE, Philippe ULg et al

in Radiation Research (2001), 155(1),

This study addressed the potential radiosensitizing effect of nicotinamide and/or carbogen on human glioblastoma xenografts in nude mice. U-87MG and LN-Z308 tumors were irradiated with either 20 fractions ... [more ▼]

This study addressed the potential radiosensitizing effect of nicotinamide and/or carbogen on human glioblastoma xenografts in nude mice. U-87MG and LN-Z308 tumors were irradiated with either 20 fractions over 12 days or 5 fractions over 5 days in air-breathing mice, mice injected with nicotinamide, mice breathing carbogen, or mice receiving nicotinamide plus carbogen. The responses to treatment were assessed using local control and moist desquamation. In U-87MG tumors, the enhancement ratios (ERs) at the radiation dose required to produce local tumor control in 50% of the treated mice (TCD50) with nicotinamide and/or carbogen ranged from 1.13 to 1.24 for irradiation in 20 fractions over 12 days. In LN-Z308 tumors, the ERs at the TCD50 with nicotinamide and/or carbogen ranged from 1.22 to 1.40 for irradiation in 5 fractions over 5 days and from 1.11 to 1.30 in 20 fractions over 12 days, respectively. Skin injury was slightly enhanced, with ERs ranged from 1.06 to 1.15 when radiation was combined with carbogen and/or nicotinamide. Thus carbogen and nicotinamide can slightly improve the radiation response of human glioblastoma xenografts. [less ▲]

Detailed reference viewed: 18 (2 ULg)
Peer Reviewed
See detailDie endoluminale, kardiovaskuläre Radiotherapie:ein neuer Standard
Coucke, Philippe ULg; Ciernik, I-F

in Praxis (2001), 90

The treatment for cardiovascular disease, especially the treatment of coronary stenosis, has been continously improving during the last decades. Routine use of angioplasty was improved by the use of ... [more ▼]

The treatment for cardiovascular disease, especially the treatment of coronary stenosis, has been continously improving during the last decades. Routine use of angioplasty was improved by the use of coronary stenting further reducing cardiac morbidity. However, the incidence of restenosis after cardiovascular angioplasty remains high. The restenosis process is mainly explained by neo-intimal proliferation. Therefore, the utility of ionizing radiation has been systematically investigated in order to reduce proliferation of the neointimal tissue. Radiation therapy turns out to be a very efficient approach in reducing the rate of both de novo lesions as well as of instant restenosis. Recent clinical data from randomized trials confirm the utility of intracoronary radiation therapy and change the treatment standards in interventional cardiology. [less ▲]

Detailed reference viewed: 12 (0 ULg)
Full Text
Peer Reviewed
See detailQuantitative short-term study of Anal sphincter function after chemoradiation for rectal cancer
Gervaz, Pascal; Rotholtz, Nicolas; Pisano, Michele et al

in Langenbeck's Archives of Surgery (2001), 136

Hypothesis: Pelvic irradiation adversely affects anal sphincter function after proctectomy with coloanal anastomosis for low rectal and middle rectal (,10 cm from the anal verge) tumors. Design: Case ... [more ▼]

Hypothesis: Pelvic irradiation adversely affects anal sphincter function after proctectomy with coloanal anastomosis for low rectal and middle rectal (,10 cm from the anal verge) tumors. Design: Case-control study. Setting: Private, tertiary care referral center. Patients: Patients treated for low rectal adenocarcinoma between January 1, 1994, and October 31, 1999. Interventions: Anal manometric data were prospectively collected at the time of initial diagnosis and before ileostomy closure. Main Outcome Measures: Mean and maximum resting pressures (RPs) and squeeze pressures, threshold volume for sensation, and maximal tolerable volume. Results: Twenty-three patients in the surgery group and 19 in the chemoradiotherapy group were considered for [less ▲]

Detailed reference viewed: 18 (1 ULg)
Full Text
Peer Reviewed
See detailIrradiation du petit bassin et fonction ano-rectale.
Gervaz, P; COUCKE, Philippe ULg; Gillet, M

in Gastroentérologie Clinique et Biologique (2001), 25

Le traitement adjuvant des cancers du rectum a pour buts de stériliser la maladie résiduelle infra-clinique et d’améliorer le contrôle local. Depuis plus de 20 ans, des milliers de malades ont été inclus ... [more ▼]

Le traitement adjuvant des cancers du rectum a pour buts de stériliser la maladie résiduelle infra-clinique et d’améliorer le contrôle local. Depuis plus de 20 ans, des milliers de malades ont été inclus dans des études randomisées, visant d’abord à mettre en évidence un gain de survie et une réduction des récidives loco-régionales, en relation avec la radiothérapie pré- ou postopératoire, combinée ou non à la chimiothérapie. Les conséquences en termes de qualité de vie de ces traitements ont pourtant été peu étudiées, et la tolérance fonctionnelle du néo-rectum et de l’appareil sphinctérien à la radiothérapie restent mal connues [1]. Les difficultés liées à l’étude des effets de l’irradiation sur les tissus normaux, ainsi que la variabilité inter-individuelle de la réponse à la radiothérapie, s’ajoutent et rendent le sujet plus complexe encore. Les radiothérapeutes adaptent leur technique afin de réduire autant que possible la dose administrée aux tissus normaux avoisinant la tumeur. Dans le cas de l’irradiation du petit bassin, c’est l’intestin grêle qui a longtemps été considéré comme la structure à risque de complications, alors que l’atteinte du sphincter anal était rarement mentionnée [2]. Malgré les répercussions importantes de la dysfonction ano-rectale sur la qualité de vie des malades, l’atteinte du sphincter anal par la radiothérapie est restée un aspect négligé du traitement adjuvant des cancers du petit bassin [3]. Cet article a pour but, à travers une revue de la littérature, de mettre en évidence les effets qualitatifs et quantitatifs de la radiothérapie sur la fonction du sphincter anal, ainsi que de proposer une modification de la technique actuelle d’irradiation des cancers du bas rectum. [less ▲]

Detailed reference viewed: 83 (2 ULg)
Full Text
Peer Reviewed
See detailRadiation therapy alone or combined surgery and radiation therapy in squamous-cell carcinoma of the penis?
Zouhair, A; COUCKE, Philippe ULg; Jeanneret, W et al

in European Journal of Cancer (2001), 37

Abstract To assess the prognostic factors and the outcome in patients with squamous-cell carcinoma of the penis, a retrospective review of 41 consecutive patients with non-metastatic invasive carcinoma of ... [more ▼]

Abstract To assess the prognostic factors and the outcome in patients with squamous-cell carcinoma of the penis, a retrospective review of 41 consecutive patients with non-metastatic invasive carcinoma of the penis, treated between 1962 and 1994, was performed. The median age was 59 years (range: 35±76 years). According to the International Union Against Cancer (UICC) 1997 classi®cation, there were 12 (29%) T1, 24 (59%) T2, 4 (10%) T3 and 1 TX (2%) tumours. The N-classi®cation was distributed as follows: 29 (71%) patients with N0, 8 (20%) with N1, 3 (7%) with N2 and 1 (2%) with N3. Forty-four per cent (n=18) of the patients underwent surgery: partial penectomy with (n=4) or without (n=12) lymph node dissection, or total penectomy with (n=1) or without (n=1) lymph node dissection. 23 patients were treated with radiation therapy alone, and all but 4 of the patients who were operated upon received postoperative radiation therapy (n=14). The median follow-up period was 70 months (range 20±331 months). In a median period of 12 months (range 5±139 months), 63% (n=26) of the patients relapsed (local in 18, locoregional in 2, regional in 3 and distant in 3). Local failure (stump in the operated patients, and the tumour bed in those treated with primary radiation therapy) was observed in 4 out of 16 (25%) patients treated with partial penectomy postoperative radiotherapy versus 14 out of 23 (61%) treated with primary radiotherapy (P=0.06). 15 (83%) out of 18 local failures were successfully salvaged with surgery. In all patients, 5- and 10-year survival rates were 57% (95% con®dence interval (CI), 41±73%) and 38% (95% CI, 21± 55%), respectively. The 5-year local and locoregional rates were 57% (95% CI, 41±73%) and 48% (95% CI, 32±64%), respectively. In patients treated with primary radiotherapy, 5- and 10-year probabilities of surviving with penis preservation were 36% (95% CI, 22±50%) and 18% (95% CI, 2±34%), respectively. In multivariate analyses, survival was signi®cantly in¯uenced by the N-classi®- cation, and surgery was the only independent factor predicting the locoregional control. We conclude that, in patients with squa- mous-cell carcinoma of the penis, local control is better in patients treated with surgery. However, there seems to be no di erence in terms of survival between patients treated by surgery and those treated by primary radiotherapy salvage surgery, with 39% having organ preservation. [less ▲]

Detailed reference viewed: 29 (1 ULg)
Full Text
Peer Reviewed
See detail33 RENO: A European surveillance registry of coronary brachytherapy with the NovosteTM Beta-CathTM System
Coen, V.; Sauerwein; Orrechia et al

in Radiotherapy & Oncology (2001), 60(supp 1), 12

Detailed reference viewed: 14 (0 ULg)
Peer Reviewed
See detailRadiothérapie vasculaire : un nouveau standard
Coucke, Philippe ULg; HU PHUOC DO; URBAN, Ph. et al

in Médecine et Hygiène (2001), 59(2342), 853-858

Le traitement des maladies cardiovasculalres, et plus spécifiquement la prise en charge des patients avec des sténoses vasculalres, qu'elles soient cardiaques ou périphériques, est en train d'être modifié ... [more ▼]

Le traitement des maladies cardiovasculalres, et plus spécifiquement la prise en charge des patients avec des sténoses vasculalres, qu'elles soient cardiaques ou périphériques, est en train d'être modifié de façon radicale. Avec l'Introduction des techniques d'angioplastie par vole transcutanée (PTCA) et la mise en place de « stents », on a certainement amélioré le devenir de ces malades. Toutefois, l'incidence de resténose après ces interventions endovasculaires reste élevée. Ce phénomène d'oblitération vasculaire après angloplastie ou stent s'explique en partie par des mécanismes de prolifération néointimale. On s'est donc logiquement tourné vers les radiations ionisantes comme alternative thérapeutique possible vu leur efficacité sur les processus de prolifération cellulaire, Autant pour les lésions de novo que les resténoses in-stent, on observe l'efficacité des radiations ionisantes. Les résultats des premiers essais randomisés ont été rendus publics et ceci va certainement changer les standards de prise en charge en cardiologie interventionnelle. [less ▲]

Detailed reference viewed: 20 (0 ULg)
Full Text
Peer Reviewed
See detailYoung Investigators Workshop participants (P.A Coucke) and N. Coleman : Radiation Research program, Radiation Oncology Sciences Program, National Cancer Institue, Nih, August 1-2, 2000
Coucke, Philippe ULg

in International Journal of Radiation, Oncology, Biology, Physics (2001), 49(5), 1505-1516

INTRODUCTION The one-and-a-half day Young Investigators Workshop was held in the Holiday Inn, Bethesda, August 1–2, 2000. Using the SCAROP mailing list and recommendations from department chiefs ... [more ▼]

INTRODUCTION The one-and-a-half day Young Investigators Workshop was held in the Holiday Inn, Bethesda, August 1–2, 2000. Using the SCAROP mailing list and recommendations from department chiefs, approximately 55 “early-career” physicianscientists were invited to attend the workshop. Table 1 includes the participants. The goals of the meeting were: c To bring together radiation oncology physician-scientists who were in the early part of their career to discuss research ideas and opportunities as well as potential barriers to progress for the field and for young-investigator careers. c To help develop camaraderie among and a critical-mass of a new generation of physician-scientists with interests ranging from technology development, to basic and translational research, to outcomes research and analysis. c To help the young investigators gain familiarity with the NIH grant programs. c To prepare a “white paper” with their vision and ideas for potential opportunities for the future. If possible, a shortand long-term agenda were to be proposed. The first morning included presentations from a variety of NCI programs. Three breakout sessions were held in the afternoon. Breakout Group Reports were discussed by the entire group the following morning. A fourth discussion topic on “Barriers To a Successful Research Career” was conducted by the entire group. Drafts of this entire Workshop Report were circulated to the participants. The final document represents the efforts of the entire Young Investigators Workshop and provides the perspective from the point of view of the investigators who have many years to invest in the future of radiation oncology. The Radiation Research Program (RRP) is grateful to all the participants for a lively workshop and to the session co-chairs for the timely preparation of this report. [less ▲]

Detailed reference viewed: 12 (2 ULg)
Peer Reviewed
See detailessai de phase II: radiothérapie accélérée préopératoire pour cancers du rectum localement avancés
COUCKE, Philippe ULg; Bouzourene, H; Gillet, M

in Cancer Radiotherapie (2000), 4(1), 204

Detailed reference viewed: 11 (1 ULg)
Peer Reviewed
See detailPathology and outcome after HART
COUCKE, Philippe ULg; Bouzourene, H

in Strahlentherapie und Onkologie (2000)

Detailed reference viewed: 1 (0 ULg)
Peer Reviewed
See detailLa resténose in-stent: la solution radiothérapeutique
COUCKE, Philippe ULg; Pica, A; Latchem, D et al

in Cancer Radiotherapie (2000), 4(1), 199

Detailed reference viewed: 3 (0 ULg)
Peer Reviewed
See detailCombination of FMdC, Tirapazamine (SR4233) and irradiation in vitro
COUCKE, Philippe ULg; Cottin, E; Stern, S et al

in International Journal of Radiation, Oncology, Biology, Physics (2000), 46(3),